Cevec Pharmaceuticals GmbH, a Cologne, Germany-based producer of tailor-made recombinant glycoproteins and gene therapy vectors, completed a €4.5m financing round.
Backers included new investors Investtodate, Frank Ubags, CEO, and Nicole Faust, CSO of Cevec as well as existing investors Peppermint VenturePartners GmbH, Creathor Venture Management, NRW.Bank, KfW Bank, G.A.T. Holding and other private individuals.
The company intends to use the funds for the development of its CAP(R)Go and CAP(R)GT platforms.
Cevec has developed and recently introduced CAP(R)Go and CAP(R)GT, which are based on a unique human cellular expression system. The CAP(R)Go expression platform comprises a portfolio of glyco-optimized human suspension cell lines for tailor-made glycosylation of recombinant proteins. The system comprises a comprehensive panel of glyco-optimized human suspension cell lines that differ in their glycosylation capabilities and allow for the recombinant production of a variety of complexly glycosylated proteins such as cytokines, ion channels, virus envelope proteins, coagulation factors and other plasma proteins. The CAP(R)GT expression platform provides a regulatory endorsed production system for gene therapy vectors with cells showing a viral spectrum supporting lentiviral (LV), adenoviral (AV) and adeno-associated viral (AAV) vectors.